AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38235512
Drug: Sovleplenib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib (600 mg q.d. for >65 kg or 400 mg q.d. for ≤65 kg)
Trial: 38235512
Drug: Sovleplenib (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sovleplenib (200-800 mg once daily or 200 mg twice daily)
Trial: 38235519
Drug: Carfilzomib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (20 mg/m2 intravenously in cycle 1 on days 1 and 2, then 56 mg/m2 from day 8 onwards), thalidomide (100 mg orally in the evening), and dexamethasone (40 mg weekly, 20 mg for patients ≥75 years) for 18 months.
Trial: 38235519
Drug: Carfilzomib, thalidomide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib, thalidomide, and dexamethasone (KTd) treatment.
Trial: 38236249
Drug: Ziv-aflibercept (2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziv-aflibercept (2-4 mg/kg) plus pembrolizumab (2 mg/kg), administered intravenously every 2 weeks
Trial: 38236431
Drug: Once-weekly subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous semaglutide (0.5 mg and 1.0 mg)
Trial: 38236431
Drug: Once-daily sitagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily sitagliptin (100 mg)
Trial: 38236575
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg twice daily with Durvalumab 1,500 mg on day 1 every 4 weeks
Trial: 38236575
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control of continued platinum-based therapy
Trial: 38236638
Drug: 7-week self-help
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-week self-help program delivered through a mobile app involving 7 weekly 10-minute videos
Trial: 38236638
Drug: Treatment-as-usual condition
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual condition (waitlist control)
Trial: 38237077
Drug: DA-EPOCH-R with
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-EPOCH-R with ixazomib (3 mg established as recommended phase 2 dose), administered for 6 cycles with ixazomib given twice per 21-day cycle; responders continued weekly ixazomib maintenance for up to 1 year.
Trial: 38237263
Drug: Mirror movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirror movement therapy ankle exercises for 15 minutes daily
Trial: 38237263
Drug: Mirror movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirror movement therapy ankle exercises for 30 minutes daily
Trial: 38237263
Drug: Mirror movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirror movement therapy ankle exercises for 50 minutes daily
Trial: 38237263
Drug: Mirror movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirror movement therapy ankle exercises for 40 minutes daily
Trial: 38237263
Drug: Mirror movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirror movement therapy ankle exercises for 35 minutes daily
Trial: 38237263
Drug: Mirror movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirror movement therapy ankle exercises (various doses)
Trial: 38237373
Drug: Surufatinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every 3 weeks)
Trial: 38237620
Drug: Controlled-release morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release morphine 5 mg orally twice daily for 14 days
Trial: 38237620
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 14 days
Trial: 38237675
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg daily for 7 days followed by 5 mg/kg daily for 7 days)
Trial: 38238052
Drug: Early resumption
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early resumption of oral intake (E group)
Trial: 38238052
Drug: Delayed resumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed resumption of oral intake (D group)
Trial: 38238050
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) after interhospital transfer
Trial: 38238055
Drug: Intraperitoneal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal irinotecan (75 mg) with concomitant mFOLFOX4 and bevacizumab
Trial: 38238182
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Structured Exercise and Lifestyle
Trial: 38238182
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to initial treatment
Trial: 38238194
Drug: EUS-guided fine
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EUS-guided fine needle injection (EUS-FNI) of large surface area microparticle paclitaxel (LSAM-PTX) at a concentration of 15 mg/mL, with a mean of 4 doses administered (mean dose/cyst: 73 ± 31 mg)
Trial: 38238599
Drug: Frequent CC
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent CC screening
Trial: 38238599
Drug: Infrequent CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrequent CC screening
Trial: 38238620
Drug: Intravenous tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tenecteplase (TNK) plus Dl-3-n-Butylphthalide (NBP)
Trial: 38238616
Drug: Allogeneic CD19-specific
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic CD19-specific CAR-NK cells expressing anti-CD19 chimeric antigen receptor and interleukin-15 (CAR19/IL-15)
Trial: 38238666
Drug: Postoperative nadir
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative nadir platelet count ≤ 99 × 10^9/L
Trial: 38238809
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (rehabilitation + optional delayed surgery)
Trial: 38239359
Drug: Apatinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (250 mg orally once daily) + Camrelizumab (200 mg)
Trial: 38240204
Drug: Low-dose edoxaban
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose edoxaban (15 mg once daily)
Trial: 38240536
Drug: Histamine-2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 receptor antagonist (SUP)
Trial: 38240791
Drug: High-dose enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose enoxaparin 30 mg q12hours (E30q12)
Trial: 38240791
Drug: Standard-dose enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose enoxaparin 40 mg q24hours (E40q24)
Trial: 38240791
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 5000 Units q8hours
Trial: 38240916
Drug: Chemotherapy (paclitaxel/docetaxel)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (paclitaxel/docetaxel)
Trial: 38241058
Drug: UFH (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH (unfractionated heparin) median dose 8000 IU; clopidogrel 600 mg
Trial: 38241059
Drug: Estetrol (E4)
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol (E4) 15 mg for 12 weeks
Trial: 38241059
Drug: Estetrol (E4)
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol (E4) 2.5 mg for 12 weeks
Trial: 38241247
Drug: Inhaled nitrous
RxNorm normalized name: nitrous oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrous oxide (1 hour at 50% concentration) plus intravenous saline (100mL)
Trial: 38241247
Drug: Inhaled oxygen
RxNorm normalized name: oxygen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled oxygen (1 hour at 50% concentration) plus intravenous midazolam (0.02 mg/kg in 100mL, up to 2mg)
Trial: 38241247
Drug: Inhaled oxygen
RxNorm normalized name: oxygen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled oxygen plus intravenous midazolam
Trial: 38241643
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg letermovir once daily orally or intravenously (240 mg with cyclosporin A)
Trial: 38241661
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins or methylprednisolone
Trial: 38242333
Drug: Behavioral Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Activation Therapy for Depression (BATD)
Trial: 38242717
Drug: Lenvatinib 20
RxNorm normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 20 mg once daily plus pembrolizumab 200 mg every 3 weeks for 35 cycles
Trial: 38242720
Drug: Immune-chemo (Ipilimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune-chemo (Ipilimumab and Nivolumab combined with anthracycline-based chemotherapy)
Trial: 38242720
Drug: Chemo-only (anthracycline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-only (anthracycline-based chemotherapy)
Trial: 38243094
Drug: Preoperative copeptin
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative copeptin (> 14 pmol·L)
Trial: 38243266
Drug: Continuous perioperative
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous perioperative ketamine infusion
Trial: 38243266
Drug: Single-dose ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ketamine in the postanesthesia care unit
Trial: 38243272
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: PAI with 100 mg bupivacaine per knee (totaling 300 mg bupivacaine for ACB and PAI)
Trial: 38243272
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: PAI with 50 mg bupivacaine per knee (totaling 200 mg bupivacaine for ACB and PAI)
Trial: 38243272
Drug: ACB combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACB combined with 100 mg bupivacaine and PAI with another 100 mg bupivacaine
Trial: 38243272
Drug: ACB combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACB combined with 100 mg bupivacaine and PAI with 200 mg bupivacaine
Trial: 38243296
Drug: Quabodepistat (QBS)
RxNorm normalized name: Quabodepistat
DrugBank: Quabodepistat (DB17770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quabodepistat (QBS) in combination with delamanid and bedaquiline for 4 months
Trial: 38243296
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (rifampicin, isoniazid, ethambutol, and pyrazinamide) for 6 months
Trial: 38243311
Drug: Broad-spectrum prophylaxis
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum prophylaxis with vancomycin 1 g and gentamicin 5 mg/kg parenterally
Trial: 38243752
Drug: Relugolix combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix combination therapy (CT) - relugolix 40 mg, oestradiol 1 mg, norethisterone acetate 0.5 mg, once daily for up to 104 weeks.
Trial: 38243752
Drug: Delayed relugolix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed relugolix CT (relugolix 40 mg monotherapy for 12 weeks, followed by relugolix CT).
Trial: 38243906
Drug: ANV419 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANV419 administered by intravenous infusion at doses of 243 µg/kg (RP2D/MTD)
Trial: 38244105
Drug: Hypofractionated chemoradiation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated chemoradiation (40 Gy of 3D-conformal RT in 15 fractions over 3 weeks with concurrent weekly cisplatin 40 mg/m2)
Trial: 38244105
Drug: Standard chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemoradiation (45 Gy in 25 fractions over 5 weeks with concurrent weekly cisplatin 40 mg/m2)
Trial: 38244384
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy-Taking it Further (MBCT-TiF)
Trial: 38244557
Drug: Oral antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antimicrobial therapy
Trial: 38244557
Drug: Intravenous standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous standard therapy
Trial: 38244557
Drug: Oral switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral switch antimicrobial therapy
Trial: 38244927
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab govitecan (SG) administered at 10 mg/kg intravenously on days 1 and 8 of 21-day cycles
Trial: 38245015
Drug: Up-front ultrasound-guided
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-front ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard pharmacological therapy
Trial: 38245015
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological therapy only
Trial: 38245724
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Ticagrelor for one month, followed by five months Ticagrelor monotherapy, and then Aspirin monotherapy for six months (Experimental group)
Trial: 38245724
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Ticagrelor for 12 months (Reference group)
Trial: 38246526
Drug: Licorice (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licorice (100 mg GA/d)
Trial: 38247010
Drug: Topical 0.05%
RxNorm normalized name: ingenol topical 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% cyclosporine A and 0.1% sodium hyaluronate
Trial: 38247190
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) oral pellets (40/10 mg) administered twice daily
Trial: 38247190
Drug: ABC/3TC (60/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABC/3TC (60/30 mg) dispersible tablets
Trial: 38249336
Drug: Recent exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent exposure to chemotherapy
Trial: 38249543
Drug: Dalbavancin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin (two doses administered 1 week apart)
Trial: 38249987
Drug: Inhaled amikacin
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled amikacin (0.4 g twice daily, 5-7 days monthly for 3 months)
Trial: 38249987
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment recommended by GOLD 2019 report
Trial: 38250251
Drug: Monoclonal gammopathy
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal gammopathy (MG) in patients with thrombotic microangiopathy (TMA)
Trial: 38250275
Drug: Electro-acupuncture (EA)
RxNorm normalized name: ELECTRODE SPRAY,ELECTRO MIST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-acupuncture (EA) and MRI-navigated rTMS therapy
Trial: 38250275
Drug: Antidepressants (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (first-line treatment for PSD)
Trial: 38250282
Drug: Two-day training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day training program based on Acceptance and Commitment Therapy (ACT)
Trial: 38251498
Drug: Mirikizumab 250
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 250 mg induction every 4 weeks for 16 weeks, then every 8 weeks from week 16 to week 52
Trial: 38251524
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg biweekly) plus maximum tolerated dose of methotrexate
Trial: 38251524
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg biweekly) plus reduced-dose methotrexate
Trial: 38251524
Drug: Adalimumab plus
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab plus maximum tolerated dose of methotrexate
Trial: 38251524
Drug: Adalimumab plus
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab plus reduced-dose methotrexate
Trial: 38251564
Drug: Tocilizumab 162
RxNorm normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 162 mg weekly subcutaneously for 12 months in combination with 8 weeks of prednisone (initial doses varied from 20 mg to 60 mg).
Trial: 38251564
Drug: Tocilizumab 162
RxNorm normalized name: TOCILIZUMAB 162MG/0.9ML AUTOINJECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 162 mg weekly subcutaneously for 12 months in combination with 8 weeks of prednisone.
Trial: 38251576
Drug: Obexelimab 5
RxNorm normalized name: Obexelimab
DrugBank: Obexelimab (DB15032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obexelimab 5 mg/kg intravenously every 2 weeks for 24 weeks
Trial: 38251576
Drug: Obexelimab treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obexelimab treatment
Trial: 38251589
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg taken orally twice a day for 12 weeks
Trial: 38251590
Drug: BMS-986142 100
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986142 100 mg
Trial: 38251590
Drug: BMS-986142 200
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-986142 200 mg
Trial: 38251601
Drug: Secukinumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (300 mg subcutaneously once a week up to week 4 and every 4 weeks thereafter)
Trial: 38251791
Drug: Fexuprazan 40
RxNorm normalized name: fexuprazan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexuprazan 40 mg once daily for 4-8 weeks
Trial: 38251791
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily for 4-8 weeks
Trial: 38251791
Drug: Fexuprazan 40
RxNorm normalized name: fexuprazan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexuprazan 40 mg
Trial: 38251861
Drug: Gel (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel (control group)
Trial: 38252423
Drug: Positive Airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Airway Pressure (PAP) treatment
Trial: 38252549
Drug: Oral Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cannabidiol Treatment
Trial: 38252908
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg intravenously once every 3 weeks for up to 2 years
Trial: 38252908
Drug: mTOR inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitor and corticosteroids (prednisone 40 mg once daily, the day before and on days 1-3 of each cycle, followed by 20 mg once daily on days 4-6, then 10 mg once daily until the day before each subsequent cycle)
Trial: 38253245
Drug: Omalizumab treatment
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab treatment for patients Inside Dosing Table (n=506)
Trial: 38253245
Drug: Omalizumab treatment
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab treatment for patients Outside Dosing Table (n=209)
Trial: 38253245
Drug: Omalizumab treatment
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab treatment for patients Insufficient Data to Recommend a Dose (n=72)
Trial: 38253318
Drug: Bilateral ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided suprazygomatic maxillary nerve block (5 ml of 0.37% ropivacaine)
Trial: 38253338
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of RSVPreF3 OA